Skip to main content

BioMedInnovations, LLC, a early stage company developing groundbreaking organ and tissue preservation technologies, today announced that it has created the role of Chief Operating Officer to accelerate the development and commercialization of its promising product portfolio and has appointed Robert (“Bob”) Neusner to this position.  In making the announcement, Chief Executive Officer Carrie DiMarzio stated “We are delighted to have an experienced executive of Bob’s caliber joining our leadership team at this critical stage in our growth.  His broad experience and past demonstrated successes will make him an asset to our company as we continue to build our team and capabilities.”

Versatility has characterized Neusner’s nearly three-decade career in the life sciences, during which time he has held a wide range of leadership positions in the commercialization and development of drugs and devices. He received a degree in chemical engineering from Rice University and an MBA from Columbia Business School, and much of his subsequent career has been spent with Johnson & Johnson, a leading pharmaceutical and medical device company,. His notable career experiences include planning launches for devices and drugs, establishing R&D and commercial partnerships, and overseeing payor strategy and patient support services for a multi-billion-dollar product franchise. Additionally, he co-invented and led the development of a diagnostic device now under ongoing approval by regulators around the globe.

“BioMedInnovations’ unique approach to organ and tissue perfusion has enormous potential to extend the viability of transplantable organs and improve the outcomes of lifesaving transplant procedures,” says Neusner. “The tremendous work put forth by the BioMedInnovations team over the past few years is coming to fruition as we ready ourselves for FDA approvals. I am honored to contribute to this dynamic, diverse, and talented team.”

About BioMedInnovations, LLC

BioMedInnovations LLC is an innovative health tech company developing groundbreaking new organ and tissue perfusion technologies with great potential to address shortages of organs for those in need of life-saving organ transplants.  Its products include the CaVESWave® system, a leading research platform for organ perfusion, and OrganBankTM, a clinical organ transport and preservation system under development.  More information about the company and its products is available at www.bmi.llc.

Leave a Reply